Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Enanta Pharma (ENTA) Misses Q4 EPS by 9c, Revenues Miss
November 21, 2019 4:01 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.44, $0.09 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.94 million.
Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSVEDP-297 selected as follow-on FXR agonist with differentiated preclinical profileRoyalty revenue for the quarter was $51.3 millionCash and marketable securities totaled approximately $400 million at September 30, 2019During 2019, we successfully... More
